Showing results (501-510 of 603) with videos related to

Sort By:
Pageof 61
Blood Cancer Journal|December 13, 2018
Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcomeAshley R Paquin, Shaji K Kumar, Francis K Buadi, et al.
American Journal of Hematology|September 9, 2018
Utility and prognostic value of 18 F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myelomaMohammed A Aljama, M Hasib Sidiqi, Francis K Buadi, et al.
Blood|March 28, 2009
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasonePrashant Kapoor, Shaji Kumar, Rafael Fonseca, et al.
Leukemia|July 31, 2020
Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosisEli Muchtar, Morie A Gertz, Taxiarchis V Kourelis, et al.
American Journal of Hematology|December 29, 2018
Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry methodSurbhi Sidana, Dragan Jevremovic, Rhett P Ketterling, et al.
Blood|January 28, 2017
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early deathEli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
British Journal of Haematology|August 2, 2021
Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemiaSaurabh Zanwar, Jithma P Abeykoon, Stephen M Ansell, et al.
Research Square|March 27, 2026
Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple MyelomaNadine Abdallah, Byron Smith, Thomas White, et al.
American Journal of Hematology|February 24, 2017
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapyAllison Rosenthal, Amylou C Dueck, Stephen Ansell, et al.
Blood Cancer Journal|January 3, 2026
Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Pageof 61